The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Predictive biomarkers in KRAS-altered NSCLC treated with checkpoint inhibitors
Natalie Vokes, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, explores a study analyzing KRAS-altered (KRASa) and KRAS-wildtype (KRASwt) non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI). Patients with PD-L1 lung cancer treated with PD-L1 inhibitors have better outcomes regardless of KRAS status. Key biomarkers, such as TP53, KEAP1, and STK11, and their role in ICI response, are also highlighted, offering insights into personalized treatment strategies for patients with KRASa and KRASwt NSCLC. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
